Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Objectives To evaluate the maternal and perinatal outcomes of pregnancies affected by SARS-CoV-2 infection.Methods This was a multinational retrospective cohort study including women with a singleton pregnancy and laboratory-confirmed SARS-CoV-2 infection, conducted in 72 centers in 22 different countries in Europe, the USA, South America, Asia and Australia, between 1 February 2020 and 30 April 2020. Confirmed SARS-CoV-2 infection was defined as a positive result on real-time reverse-transcription polymerase chain reaction (RT-PCR) assay of nasopharyngeal swab specimens. The primary outcome was a composite measure of maternal mortality and morbidity, including admission to the intensive care unit (ICU), use of mechanical ventilation and death.Results In total, 388 women with a singleton pregnancy tested positive for SARS-CoV-2 on RT-PCR of a nasopharyngeal swab and were included in the study. Composite adverse maternal outcome was observed in 47/388 (12.1%) women; 43 (11.1%) women were admitted to the ICU, 36 (9.3%) required mechanical ventilation and three (0.8%) died. Of the 388 women included in the study, 122 (31.4%) were still pregnant at the time of data analysis. Among the other 266 women, six (19.4% of the 31 women with first-trimester infection) had miscarriage, three (1.1%) had termination of pregnancy, six (2.3%) had stillbirth and 251 (94.4%) delivered a liveborn infant. The rate of preterm birth before 37 weeks' gestation was 26.3% (70/266). Of the 251 liveborn infants, 69/251(27.5%) were admitted to the neonatal ICU, and there were five (2.0%) neonatal deaths. The overall rate of perinatal death was 4.1% (11/266). Only one (1/251, 0.4%) infant, born to a mother who tested positive during the third trimester, was found to be positive for SARS-CoV-2 on RT-PCR.Conclusions SARS-CoV-2 infection in pregnant women is associated with a 0.8% rate of maternal mortality, but an 11.1% rate of admission to the ICU. The risk of vertical transmission seems to be negligible. (C) 2020 International Society of Ultrasound in Obstetrics and Gynecology.
Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection
Gabriele Saccone;Cihat Sen;Daniele Di Mascio;Alberto Galindo;Amos Gr??nebaum;Jun Yoshimatsu;Milan Stanojevic;As??m Kurjak;Frank Chervenak;Mar??a Jos?? Rodr??guez Su??rez;Zita Maria Gambacorti???Passerini;Mar??a de los Angeles Anaya Baz;Esther Vanessa Aguilar Gal??n;Yolanda Cu??arro L??pez;Juan Antonio De Le??n Luis;Ignacio Cueto Hern??ndez;Ignacio Herraiz;Cecilia Villalain;Roberta Venturella;Giuseppe Rizzo;Ilenia Mappa;Giovanni Gerosolima;Lars Hellmeyer;Josefine K??nigbauer;Giada Ameli;Tiziana Frusca;Nicola Volpe;Giovanni Battista Luca Schera;Stefania Fieni;Eutalia Esposito;Giuliana Simonazzi;Gaetana Di Donna;Aly Youssef;Anna Nunzia Della Gatta;Mariano Catello Di Donna;Vito Chiantera;Natalina Buono;Giulio Sozzi;Pantaleo Greco;Danila Morano;Beatrice Bianchi;Maria Giulia Lombana Marino;Federica Laraud;Arianna Ramone;Angelo Cagnacci;Fabio Barra;Claudio Gustavino;Simone Ferrero;Fabio Ghezzi;Antonella Cromi;Antonio Simone Lagan??;Valentina Laurita Longo;Francesca Stollagli;Angelo Sirico;Antonio Lanzone;Lorenza Driul;Fabiana Cecchini;Serena Xodo;Brian Rodriguez;Felipe Mercado???Olivares;Deena Elkafrawi;Giovanni Sisti;Rosanna Esposito;Antonio Coviello;Marco Cerbone;Maddalena Morlando;Antonio Schiattarella;Nicola Colacurci;Pasquale De Franciscis;Ilaria Cataneo;Marinella Lenzi;Fabrizio Sandri;Riccardo Buscemi;Giorgia Gattei;Francesca Della Sala;Eleonora Valori;Maria Cristina Rovellotti;Elisa Done;Gilles Faron;Leonardo Gucciardo;Valentina Esposito;Flaminia Vena;Antonella Giancotti;Roberto Brunelli;Ludovico Muzii;Luigi Nappi;Felice Sorrentino;Marco Liberati;Danilo Buca;Martina Leombroni;Francesca Di Sebastiano;Massimo Franchi;Quintino Cesare Ianniciello;Simone Garzon;Giuliano Petriglia;Leonardo Borrello;Albaro Jos?? Nieto???Calvache;Juan Manuel Burgos???Luna;Caroline Kadji;Andrew Carlin;Elisa Bevilacqua;Marina Moucho;Pedro Viana Pinto;Rita Figueiredo;Jos?? Morales Rosell??;Gabriela Loscalzo;Alicia Martinez???Varea;Vincente Diago;Jes??s S Jimenez Lopez;Alicia Yeliz Aykanat;Stefano Cosma;Andrea Carosso;Chiara Benedetto;Amanda Bermejo;Otto Henrique May Feuerschuette;Ozlem Uyaniklar;Sakine Rahimli Ocakouglu;Zeliha Atak;Reyhan G??nd??z;Esra Tustas Haberal;Bernd Froessler;Anupam Parange;Peter Palm;Igor Samardjiski;Chiara Taccaliti;Erhan Okuyan;George Daskalakis;Renato Augusto Moreira de Sa;Alejandro Pittaro;Maria Luisa Gonzalez???Duran;Ana Concheiro Guisan;??erife ??zlem Gen??;Blanka Zlatohl??vkov??;Anna Luengo Piqueras;Dolores Esteban Oliva;Aylin Pelin Cil;Olus Api;Panos Antsaklis;Liana Ples;Ioannis Kyvernitakis;Holger Maul;Marcel Malan;Albert Lila;Roberta Granese;Alfredo Ercoli;Giuseppe Zoccali;Andrea Villasco;Nicoletta Biglia;Ciuhodaru Madalina;Elena Costa;Caroline Daelemans;Axelle Pintiaux;Elif G??l Yapar Eyi;Elisa Cueto;Eran Hadar;Sarah Dollinger;Noa A. Brzezinski???Sinai;Erasmo Huertas;Pedro Arango;Amadeo Sanchez;Javier Alfonso Schvartzman;Liviu Cojocaru;Sifa Turan;Ozhan Turan;Maria Carmela Di Dedda;Rebeca Garrote Molpeceres;Snezana Zdjelar;Tanja Premru???Srsen;Lilijana Kornhauser???Cerar;Mirjam Dru??kovi??;Valentina De Robertis;Vedran Stefanovic;Irmeli Nupponen;Kaisa Nelskyl??;Zulfiya Khodjaeva;Ksenia A. Gorina;Gennady T. Sukhikh;Giuseppe Maria Maruotti;Silvia Visentin;Erich Cosmi;Jacopo Ferrari;Alessandra Gatti;Daniela Luvero;Roberto Angioli;Ludovica Puri;Marco Palumbo;Giusella D'Urso;Francesco Colaleo;Agnese Maria Chiara Rapisarda;Ilma Floriana Carbone;Lamberto Manzoli;Maria Elena Flacco;Giovanni Nazzaro;Mariavittoria Locci;Maurizio Guida;Attilio Di Spiezio Sardo;Pierluigi Benedetti Panici;Asma Khalil;Vincenzo Berghella;Giuseppe Bifulco;Giovanni Scambia;Fulvio Zullo;Francesco D'Antonio
2021-01-01
Abstract
Objectives To evaluate the maternal and perinatal outcomes of pregnancies affected by SARS-CoV-2 infection.Methods This was a multinational retrospective cohort study including women with a singleton pregnancy and laboratory-confirmed SARS-CoV-2 infection, conducted in 72 centers in 22 different countries in Europe, the USA, South America, Asia and Australia, between 1 February 2020 and 30 April 2020. Confirmed SARS-CoV-2 infection was defined as a positive result on real-time reverse-transcription polymerase chain reaction (RT-PCR) assay of nasopharyngeal swab specimens. The primary outcome was a composite measure of maternal mortality and morbidity, including admission to the intensive care unit (ICU), use of mechanical ventilation and death.Results In total, 388 women with a singleton pregnancy tested positive for SARS-CoV-2 on RT-PCR of a nasopharyngeal swab and were included in the study. Composite adverse maternal outcome was observed in 47/388 (12.1%) women; 43 (11.1%) women were admitted to the ICU, 36 (9.3%) required mechanical ventilation and three (0.8%) died. Of the 388 women included in the study, 122 (31.4%) were still pregnant at the time of data analysis. Among the other 266 women, six (19.4% of the 31 women with first-trimester infection) had miscarriage, three (1.1%) had termination of pregnancy, six (2.3%) had stillbirth and 251 (94.4%) delivered a liveborn infant. The rate of preterm birth before 37 weeks' gestation was 26.3% (70/266). Of the 251 liveborn infants, 69/251(27.5%) were admitted to the neonatal ICU, and there were five (2.0%) neonatal deaths. The overall rate of perinatal death was 4.1% (11/266). Only one (1/251, 0.4%) infant, born to a mother who tested positive during the third trimester, was found to be positive for SARS-CoV-2 on RT-PCR.Conclusions SARS-CoV-2 infection in pregnant women is associated with a 0.8% rate of maternal mortality, but an 11.1% rate of admission to the ICU. The risk of vertical transmission seems to be negligible. (C) 2020 International Society of Ultrasound in Obstetrics and Gynecology.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12610/76255
Citazioni
100
155
123
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.